Envisia initiates phase 2a clinical trial for glaucoma treatment

Envisia Therapeutics initiated a phase 2a clinical trial to investigate the safety and tolerability of ENV515 in glaucoma patients, according to a press release. ENV515 is a biodegradable particle replication in non-wetting templates (PRINT) formulation of travoprost and may reduce IOP for up to 6 months, the release said.